Free Trial

DaVita (NYSE:DVA) Posts Earnings Results, Misses Expectations By $0.17 EPS

DaVita logo with Medical background

DaVita (NYSE:DVA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17), Briefing.com reports. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the prior year, the company earned $2.85 earnings per share. The business's quarterly revenue was up 4.6% compared to the same quarter last year. DaVita updated its FY24 guidance to $9.25-$10.05 EPS and its FY 2024 guidance to 9.250-10.050 EPS.

DaVita Trading Down 11.7 %

Shares of DaVita stock traded down $18.48 during midday trading on Wednesday, reaching $139.83. 1,934,443 shares of the company's stock traded hands, compared to its average volume of 810,290. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The stock has a 50 day moving average of $158.40 and a 200-day moving average of $146.05. The company has a market cap of $11.73 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. DaVita has a 12 month low of $76.17 and a 12 month high of $168.50.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of recent analyst reports. Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. TD Cowen increased their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a research report on Wednesday, July 24th. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. Finally, Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, DaVita has an average rating of "Hold" and an average price target of $159.00.

Read Our Latest Stock Report on DVA

Insider Buying and Selling at DaVita

In other news, CFO Joel Ackerman sold 64,029 shares of the firm's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Javier Rodriguez sold 32,176 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the business's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by corporate insiders.

DaVita Company Profile

(Get Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

Earnings History for DaVita (NYSE:DVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in DaVita right now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines